- Home
- IMTX
IMTX
Immatics N.V.
as 10-23-2025 3:54pm EST
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
| Founded: | N/A | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 865.5M | IPO Year: | N/A |
| Target Price: | $13.67 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.30 - $11.25 | Next Earning Date: | 11-17-2025 |
| Revenue: | $152,823,253 | Revenue Growth: | 83.61% |
| Revenue Growth (this year): | -71% | Revenue Growth (next year): | 13.53% |
Latest Immatics N.V. News
IMTX Breaking Stock News: Dive into IMTX Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Guggenheim Initiates Coverage on Immatics N.V With Buy Rating, $16 Price Target
GlobeNewswire
5 months ago
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Simply Wall St.
5 months ago
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
GlobeNewswire
5 months ago
Immatics Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
6 months ago
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Simply Wall St.
7 months ago
Immatics Full Year 2024 Earnings: Beats Expectations
GlobeNewswire
7 months ago
Immatics Announces Full Year 2024 Financial Results and Business Update
Simply Wall St.
8 months ago
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year
Compare IMTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMTX Immatics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.